Parnassus Growth Equity Fund Q2 2026 Portfolio Activity

Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing.

Summary - Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing. - Lumentum offers exposure to a key bottleneck in AI infrastructure, optical networking, as rising data demand drives a shift away from copper-based systems. - Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales.

- We exited Boston Scientific as the competitive environment evolved more quickly than anticipated. - We sold Salesforce as conviction in horizontal application software declined amid increased competition and weaker pricing dynamics. Since 1984, Parnassus Investments has invested differently.

Parnassus' single investment team curates concentrated portfolios of high-quality companies that are financially strong and take care of the human and natural resources upon which their businesses rely in the pursuit of enduring value. Note: This account is not managed or monitored by Parnassus Investments, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use Parnassus Investments' official channels.